ArticleInternational journal of women's health2026
Predictive Value of Serum Pentraxin 3 and Galectin-3 in Early Pregnancy for Gestational Diabetes Mellitus in Chinese Women.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Gestational diabetes mellitus (GDM) is a common metabolic complication during pregnancy. Early identification of high-risk women is critical for reducing maternal and fetal complications. This study aimed to explore the predictive value of serum pentraxin 3 (PTX3) and galectin-3 in early pregnancy for GDM among Chinese women. Methods: This retrospective case-control study recruited pregnant women with a first prenatal visit before 14 weeks of gestation. Serum samples were collected at enrollment. All participants were followed up to 24-28 weeks, and GDM was confirmed via standard 75 g oral glucose tolerance test (OGTT). Correlation analysis, ROC curve and binary logistic regression were used to evaluate predictive efficacy. A total of 120 eligible women were divided into the GDM group (n=60) and healthy control group (n=60). Results: FBG, FINS, PTX3 and galectin-3 levels were markedly elevated in GDM group (P < 0.05). Both biomarkers were positively correlated with glucose and insulin indexes (P < 0.05). The AUC values of PTX3 and galectin-3 were 0.821 and 0.662 respectively. The combined detection yielded an AUC of 0.877, with a sensitivity of 86.5% and a specificity of 92.3%. PTX3 and galectin-3 were verified as independent risk factors of GDM. Conclusion: First-trimester PTX3 and galectin-3 can serve as effective biomarkers for GDM prediction. Combined detection improves diagnostic efficiency and facilitates early screening for high-risk populations. Due to the single-center design and 1:1 grouping inconsistent with actual GDM prevalence, further prospective multicenter studies are required to validate our findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.